A meta-analysis of safety and efficacy of regorafenib for refractory metastatic colorectal cancer

BACKGROUND: Patients with metastatic colorectal cancer (mCRC) often suffer from progressive disease despite previous therapy. It has been a great challenge for those patients. In 2012, regorafenib was approved for mCRC. In this meta-analysis, we aimed to collect and present existing data to exploret...

Descripción completa

Detalles Bibliográficos
Autores principales: Xue, Wu-Song, Men, Si-Ye, Liu, Wei, Liu, Reng-Hai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6200445/
https://www.ncbi.nlm.nih.gov/pubmed/30290640
http://dx.doi.org/10.1097/MD.0000000000012635

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6200445/
https://www.ncbi.nlm.nih.gov/pubmed/30290640
http://dx.doi.org/10.1097/MD.0000000000012635

Ejemplares similares